Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-finding study of subcutaneous T502 for birch pollen-induced allergic rhinoconjunctivitis
2018-002522-23Phase 2Completed
- Sponsor
- Inmunotek
- Start
- Mar 2019
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of birch pollen allergen extract in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) (4 arms), sponsored by Inmunotek. Primary endpoint: Combined Symptom and Medication Score over peak pollen period 2020. Started Mar 2019; status: completed.
02
Drugs
birch pollen allergen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2018-002522-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002522-23.